Regulated information
Seneffe - Belgium, November 8, 2013, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its financial results for the third quarter of 2013.
The report including the milestones and a selection of consolidated key figures of the third quarter of 2013 can be downloaded at:
www.bebig.eu:
http://www.bebig.eu > Investor Relations > Financial Reports
Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group, active in the medical device sector of the healthcare industry.
Its core business is the treatment of cancer by brachytherapy, a special form of radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and is headquartered in Belgium. It has a production facility in Germany and subsidiaries throughout Europe, in the USA, India and Brazil. Eckert & Ziegler BEBIG has also established a worldwide network of distributors and agents to support its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs about 200 people. It has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB).
Contact:
Eckert & Ziegler BEBIG s.a.
Investor Relations
Tel: +32 (0) 64 520 808
E-mail: ir@bebig.eu:
mailto:ir@bebig.eu
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE